This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

The Cigna Group
11/5/2026
Ladies and gentlemen, thank you for standing by for the Cigna Group's third quarter 2026 results review. At this time, all callers are in a listen-only mode. We will conduct a question and answer session later during the conference and review procedures on how to enter queue to ask questions at that time. If you should require assistance during the call, please press star zero on your touchtone phone. As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded. We'll begin by turning the conference over to Ralph Giacobbe. Please go ahead.
Great, thanks. Good morning. Thank you for joining today's call. I'm Ralph Giacobbe, Senior Vice President of Investor Relations. With me on the line this morning are Brian Evanko, the Cigna Group's President and Chief Executive Officer, and Ann Dennison, Chief Financial Officer. In our remarks today, Brian and Ann will cover a number of topics, including our third quarter 2026 financial results and our financial outlook for 2026. Following their prepared remarks, Brian and Ann will be available for Q&A. As noted in our earnings release, when describing our financial results, we use certain financial measures, including adjusted income from operations and adjusted revenues, which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. A reconciliation of these measures to the most directly comparable GAAP measures, shareholders net income, and total revenues, respectively, is contained in today's earnings release, which is posted in the investor relations section of the CignaGroup.com. We use the term labeled adjusted income from operations and adjusted earnings per share on the same basis as our principle measures of financial performance. In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2026 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC. Regarding our results in the third quarter, we recorded after tax special item charges of $146 million or 55 cents per share. Details of the special items are included in our quarterly financial supplement. Additionally, please note that when we make perspective comments regarding financial performance, including our full year 2026 outlook, we will do so on a basis that includes the potential impact of future share of purchases and anticipated 2026 dividends. With that, I'll turn the call over to Brian.
Thanks, Ralph. Good morning, everyone, and thank you for joining our call. I'm pleased to share that the Cigna Group delivered strong performance in the third quarter as we continue executing on our strategy. Today I'll cover our results for the quarter and key drivers, our profitable growth strategy, and how we're advancing toward our long-term EPS growth algorithm of 10% to 14%, which we laid out in our recent investor day, as well as how our strategic growth framework positions us to build momentum in 2027. Then Ann will share additional details about our financial results and outlook for the rest of the year. and we'll take your questions. During the quarter we delivered adjusted revenue of $73.8 billion, adjusted after tax earnings of $2.1 billion and adjusted earnings per share of $7.98. The work we've done over several years to deliberately shape our portfolio is delivering results and we are built for the fastest growing areas of healthcare with a proven ability to execute through a dynamic environment. Our strong performance through the first nine months of the year gives us confidence to raise our full-year outlook, and we now expect adjusted earnings per share of at least $30.60. And importantly, we are building on that strong foundation as we look beyond 2026. At our recent investor day, we announced our Lead to One vision, which is centered on delivering personalization at scale to improve affordability and the healthcare experience for every customer and patient we serve. Lead to One brings together all of our medical, pharmacy, behavioral health, and specialty care capabilities around the individual. By responsibly leveraging our data, clinical expertise, and technology, we can identify needs earlier, deliver more personalized support, and improve health outcomes while lowering the total cost of care. Our Lead to One vision will benefit all customers, and we see a particular opportunity with the most clinically complex patient needs. where healthcare costs are increasingly concentrated and represent over 50% of total healthcare spending. Lead to One is underpinned by a clear strategic growth framework comprised of three pillars. First, we will deliver core growth. Second, we will leverage distinct capabilities. And third, we will execute with discipline. These three pillars taken together give us a clear path to build on the strength of our business today while creating the next chapter of sustainable growth and greater value for those we serve. Now let me walk through some of our highlights in the quarter across Evernorth Health Services and Cigna Healthcare. Starting in Evernorth, third quarter earnings were in line with expectations. Our specialty and care services businesses delivered attractive performance, including pre-tax adjusted earnings growth of 15% year-over-year. This was fueled by secular tailwinds and disciplined execution across our specialty pharmacy and distribution capabilities. We also drove continued strong biosimilar and specialty generic utilization. Today, Revlimid, a widely used oncology drug, is seeing specialty generic adoption rates around 90%. Across our specialty businesses, we are leveraging our distinct capabilities for patients with complex needs who require a higher level of care, support, and coordination to manage their conditions. For example, in our specialty pharmacy at Credo, we have industry-leading access with more than 330 highly complex, limited distribution and exclusive products. This demonstrates the strength of our manufacturer relationships and the trust they place in us to partner in serving some of the most clinically complex patient needs. That access also positions us to capture growth as new specialty therapies come to market. I'm also pleased to share that we continue to expand our capacity for these limited distribution products with our network of clean rooms, the fifth of which is now in a build phase. These highly sterile environments take years to build, license, and operationalize to safely mix and compound some of the most complex medicines. These clean rooms are just one example of the durable competitive advantage in our specialty business that we've constructed over the past few decades. Finally, our expanded distribution channels are unlocking new opportunities. CuraScript SD is a leader in specialty distribution with access to 40 exclusive distribution drugs. And our recently launched Evernorth Wholesale has begun fulfilling orders to our distribution centers to be able to serve customers. In our pharmacy benefits services business in Evernorth, we delivered third quarter pre-tax adjusted earnings of $765 million. We continue to see strong momentum for the 2027 sale season, supporting our core growth, along with strong retention rates in the high 90s. Next, I'd like to spend a moment on our signature model transition. We are pioneering this new approach to pharmacy benefits and want you to have further context around current status and why we're so confident in our path. You can think of our signature implementation in three broad phases. Phase 1, our design phase, is complete. Announced this time last year, Phase 1 included designing signature, our market-defining innovation, driven by core principles of affordability, simplicity, transparency, and value. Inherent in the model is our price-assured capability, which is designed to ensure patients pay the lowest available out-of-pocket cost when they fill prescriptions and will save an average of 30% on high-cost branded drugs. Price Assure is already in market and being leveraged by about 10% of our current clients. And the signature model is consistent with the direction of regulatory changes, including the Consolidated Appropriations Act of 2026 and the Department of Labor's recently finalized PBM fee disclosure rule. Phase two, our build phase, is well underway. Currently, we're working on adoption planning alongside market education. Key stakeholders include brokers, pharmaceutical manufacturers, network pharmacy partners, and clients. The work is largely complete for brokers, and we're actively advancing contracts with pharmaceutical manufacturers and network pharmacies. Phase three, our adoption phase is on track. The next milestone is the adoption of signature for our Cigna Healthcare Fully Insured book on 1-1-27. Early client conversations for the 2028 benefits year have been encouraging. and indicate strong interest in the model for a broader Evernorth book of pharmacy benefit services clients. And our very strong 2027 selling season reinforces that clients value innovation and see us as a multi-year partner on their pharmacy benefits journey. Clients see value in signatures focused on patient affordability and transparency and in how it supports their efforts to meet evolving regulatory requirements and their fiduciary responsibilities. They also see a model that can encourage adherence with improved health outcomes and workforce productivity. In summary, we're proud of the progress we're making on Signature. We've completed phase one and are on track to deliver against phases two and three with broader client adoption expected to ramp in 2028. We'll share some further detail on the progress across phases two and three during our fourth quarter earnings call. Finally, we continue to leverage our distinct capabilities in pharmacy benefit services to generate industry-leading affordability outcomes. including our deep supply chain expertise, clinical safety checks, and connectivity in the rapidly evolving pharmaceutical market to meet the needs of clients and customers. And we're continuing to enhance our technology platforms, better connecting the different components of the pharmacy benefit to create a simpler, more flexible experience for patients and clients. Turning to Cigna Healthcare, we delivered another quarter of strong growth with results ahead of expectations. with pre-tax adjusted earnings growth of 15% year-over-year. Our disciplined pricing, coupled with advanced analytics and insights, enable our steady medical care ratio performance. While medical cost trends continue to be elevated, they are consistent with our expectations and pricing assumptions. This quarter, we also benefited from stronger net investment income and favorable SG&A performance. We also introduced new capabilities in Cigna Healthcare in September with the launch of HealthSense, our data and technology powered customer engagement solution that will start with oncology but broaden to other conditions over time. By connecting a customer's health needs, benefits, pharmacy coverage, costs, claims, and prior interactions, our clinical teams have context and a more complete picture enabling earlier interventions. As a reminder, costs are increasingly concentrated in complex conditions, with 8% of patients generating 55% of total healthcare spent. We're excited about the early positive reception to HealthSense from clients and customers, and are taking an agile approach to launching additional components as they are built. As we look to 2027, we remain confident in the strength of our strategic growth framework and our ability to perform through a dynamic environment. During our fourth quarter call, we will provide our comprehensive 2027 guidance. We continue to expect adjusted earnings per share growth of at least 10% in 2027 off our run rate earnings for our ongoing businesses and remain confident in 2030 adjusted earnings per share of at least $45 that we outlined in our investor day. Today, I'll briefly cover the primary tailwinds and headwinds for 2027. Starting with the tailwinds, First, in our Cigna Healthcare business, we are driving continued improvement in our stop loss margins. Second, we're pleased with a strong 2027 selling season in both Evernorth and Cigna Healthcare. High client retention and new business wins reinforce the strength of our value proposition and innovation and will contribute to attractive enterprise revenue growth in 2027. And third, our Accelerate to One Modernization and Productivity Initiative will drive savings across the enterprise. Turning to the headwinds we expect in 2027. First, within Evernorth Pharmacy Benefit Services, the compression of industry rebate pools and lower employer coverage of GLP-1s for weight loss, consistent with our commentary from Investor Day. Second, within Evernorth Specialty and Care Services, a more limited pipeline of biosimilar and specialty generic launches in the coming year. And finally, as you'd expect, the known exit from the ACA Exchange business will remove that contribution from Cigna Healthcare. To ensure our success, we're focused on disciplined execution across the enterprise. Part of our DNA is our proven ability to evolve. Throughout our 234-year history, we've continuously adapted to lead through change and innovated to drive what comes next. Across our businesses, we're coupling data and insights with our clinical and analytical expertise. resulting in disciplined pricing, timely patient support, and consultative solutions for clients. And we're building a future-ready, efficient, and effective workforce while optimizing accountability and decision-making with our Accelerate to One initiative, all while driving run rate savings of $3 billion by 2030, which you'll hear more about from Ann in a few moments. Now let me close with a few key takeaways. First, we are generating core growth in each of our three business platforms. We've deliberately shaped our portfolio with capabilities that are focused on the most attractive subsectors of healthcare where needs and spending are concentrated with multiple growth engines across specialty and care services and pharmacy benefit services in Evernorth along with Cigna Healthcare. Second, we are leveraging our distinct capabilities that strengthen our position for the future. Our expertise in complex care combined with our clinical capabilities, data, advanced analytics and AI enables us to deliver greater personalization at scale, improve affordability, and create more value for the people we serve. You see that strategy coming to life through capabilities like HealthSense, our expanding specialty infrastructure, and continued innovation across our pharmacy businesses. Third, disciplined execution continues to differentiate our company. This quarter, that showed up in strong client demand, disciplined pricing, stable medical cost trends, continued specialty growth, and our ability to adapt our solutions as the market evolves. And as we look to 2027, we have clear visibility into the puts and takes ahead and have multiple levers across the enterprise to deliver against our commitments. Importantly, we are not dependent on any one single business, market trend or innovation to deliver our long-term expectations. Our third quarter performance reinforces our confidence in our Lead to One vision and in our long-term strategy. leading to durable, profitable growth and compelling long-term shareholder value creation. With that, I'll turn it over to Ann.
You're reading a preview of the CI Q3 2026 earnings call.
Free account.